#21
JOURNAL ARTICLE
Edwin S Chen, Mark A Terry, Neda Shamie, Karen L Hoar, Daniel J Friend
PURPOSE: To report 6-month results in a large, prospective study of Descemet-stripping automated endothelial keratoplasty (DSAEK). METHODS: A 5-mm scleral-limbal tunnel approach was created for placement of an automated microkeratome-prepared 8.0-mm endothelial graft after DSAEK in 150 consecutive cases between September 2005 and October 2006. Six-month follow-up data were available on 100 eyes. Intraoperative peripheral scraping was performed to promote adherence of the donor...
June 2008: Cornea
#22
RANDOMIZED CONTROLLED TRIAL
Mark B Abelson, Paul J Gomes, Terri Pasquine, Michael R Edwards, Robert D Gross, Stella M Robertson
Olopatadine hydrochloride ophthalmic solution 0.2% (Pataday, Alcon) is a new formulation of olopatadine hydrochloride ophthalmic solution, the first topical ocular antiallergic agent indicated for once-daily dosing. The aim of this study was to evaluate the safety, efficacy, onset, and duration of action of olopatadine 0.2% in the treatment of allergic conjunctivitis. Using the conjunctival allergen challenge, this double-masked, randomized by eye, parallel-group study included four visits over a 5-week period...
July 2007: Allergy and Asthma Proceedings:
#23
RANDOMIZED CONTROLLED TRIAL
Mark B Abelson, Paul J Gomes, Cullen T Vogelson, Terri A Pasquine, F Darell Turner, David T Wells, Stella M Robertson
BACKGROUND: A new formulation of olopatadine hydrochloride ophthalmic solution (olopatadine 0.2%) was evaluated in two separate, randomized, placebo-controlled, double-masked, hybrid environmental studies intended to determine efficacy and safety in subjects with histories of seasonal allergic conjunctivitis or rhinoconjunctivitis. DESIGN AND METHODS: In these 10- and 12-week trials (conducted April-August 2003 and July-December 2001, respectively), subjects assessed their ocular signs and symptoms...
May 2005: Current Medical Research and Opinion
#24
JOURNAL ARTICLE
L Bercovitch, T Leroux, S Terry, M A Weinstock
BACKGROUND: Pseudoxanthoma elasticum (PXE) is a genetic multisystem disorder characterized by calcified dystrophic elastic fibres in skin, retina and arteries. Much of the earlier literature on pregnancy in PXE contained reports of severe complications, leading some healthcare providers to advise women with PXE against becoming pregnant and some women with PXE to avoid pregnancy. OBJECTIVES: To evaluate the obstetrical outcomes and the incidence of pregnancy complications in women with PXE and to determine if pregnancy is associated with an adverse effect on the course of the disease...
November 2004: British Journal of Dermatology
#25
RANDOMIZED CONTROLLED TRIAL
Mark B Abelson, Paul J Gomes, Cullen T Vogelson, Terri A Pasquine, Robert D Gross, F Darell Turner, David T Wells, Michael V W Bergamini, Stella M Robertson
BACKGROUND: Previous studies have suggested that olopatadine hydrochloride ophthalmic solution 0.2% administered once daily is effective for up to 24 hours after instillation and is well tolerated in adults and children aged > or =3 years. OBJECTIVE: The goal of this study was to evaluate the efficacy and safety profile of olopatadine 0.2% compared with placebo in patients with seasonal allergic conjunctivitis or rhinoconjunctivitis. METHODS: This was a 10-week, randomized, placebo-controlled, double-masked environmental study conducted during the spring allergy season (April-August) of 2003...
August 2004: Clinical Therapeutics
#26
RANDOMIZED CONTROLLED TRIAL
Cullen T Vogelson, Mark B Abelson, Terri Pasquine, Donna M Stephens, Daniel A Gamache, Robert D Gross, Stella M Robertson, John M Yanni
Pharmacologic studies examined the potential of a solution containing olopatadine to maintain and extend antiallergic efficacy after single topical ocular drop administration over 24 hours. Results of these preclinical experiments conducted in guinea pigs indicated that olopatadine 0.2% (wt/vol) solution was significantly effective 24 hours after dosing. This concentration of olopatadine provided significantly more efficacy than Patanol (olopatadine 0.1%) 24 hours after administration while being as effective as Patanol (olopatadine 0...
January 2004: Allergy and Asthma Proceedings:
#27
JOURNAL ARTICLE
Mark A Terry, Paula J Ousley
PURPOSE: To determine if the new technique for endothelial transplantation of DLEK (deep lamellar endothelial keratoplasty) can offer predictable corneal curvature and improved refractive spherical equivalent results compared with reports for traditional penetrating keratoplasty. METHODS: Twenty-seven consecutive Fuchs corneal dystrophy patients received DLEK surgery to replace their endothelium. Topographic corneal curvature and refractive spherical equivalents were evaluated at preop and at 6 and 12 months postop...
October 2003: Cornea
#28
JOURNAL ARTICLE
R L Black, J E Terry
Thrombotic thrombocytopenic purpura is a serious and uncommon disease of hemostasis. Severe disturbances in both blood components and chemistry may cause marked changes both systemically and in ocular tissues. Ocular manifestations include retinal and vitreal hemorrhage, retinal detachment, papilledema, and disc neovascularization. Management of mild cases is limited to supportive therapy and monitoring changes in the fundus. In advanced cases, photocoagulation, vitrectomy, and retinal reattachment surgery may be necessary...
June 1991: Journal of the American Optometric Association
1